


AZD3264

Cat. No.:	HY-19362		
CAS No.:	1609281-86-8		
Molecular Formula:	C ₂₁ H ₂₃ N ₅ O ₄ S		
Molecular Weight:	441.5		
Target:	IKK		
Pathway:	NF-κB		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	2 years
		-20°C	1 year



SOLVENT & SOLUBILITY

In Vitro

DMSO : ≥ 48 mg/mL (108.72 mM)
 * "≥" means soluble, but saturation unknown.

Preparing Stock Solutions	Solvent		Mass		
	Concentration		1 mg	5 mg	10 mg
	1 mM		2.2650 mL	11.3250 mL	22.6501 mL
	5 mM		0.4530 mL	2.2650 mL	4.5300 mL
	10 mM		0.2265 mL	1.1325 mL	2.2650 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
 Solubility: ≥ 2.5 mg/mL (5.66 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% corn oil
 Solubility: ≥ 2.5 mg/mL (5.66 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

AZD3264 is a selective IκB-kinase IKK2 inhibitor.

IC₅₀ & Target

IKK2

In Vivo

AZD3264 is a selective IκB-kinase IKK2 inhibitor, which is currently in preclinical development for the potential treatment of chronic pulmonary obstructive disorder (COPD) and asthma^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

CUSTOMER VALIDATION

- Cell Cycle. 2022 Jun 28;1-13.
- J AOAC Int. 2021 May 21;104(2):348-354.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Andiappan Murugan, et al. Exploiting the Differential Reactivities of Halogen Atoms: Development of a Scalable Route to IKK2 Inhibitor AZD3264. Org Process Res Dev. 2014 Apr 29;18(5): 646-651.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA